STUDY ABOUT THE STUDY ABOUT THE CADILA PHARMACEUTICAL CADILA PHARMACEUTICAL LIMITEDLIMITED

PREPARE BY-PREPARE BY-SANTOSH KUMARSANTOSH KUMARPGDMM-09/006PGDMM-09/006

About Cadila Pharmaceuticals Limited Cadila Pharmaceuticals Ltd., established in 1951, is a true Life Sciences company and over the years has emerged as the undisputed leader with largest range of therapeutic groups. The company covers the entire gamut of pharmaceuticals

HISTORYHISTORY

Largest privately held pharmaceutical companies in India Largest privately held pharmaceutical companies in India

Headquarter at AhmedabadHeadquarter at Ahmedabad

PI plants located at Ankleshwar, Vadodra and PatalgangaPI plants located at Ankleshwar, Vadodra and Patalganga

It has best Research and Development setups in IndiaIt has best Research and Development setups in India

It is manned by 350 scientists and engineers It is manned by 350 scientists and engineers

•They are from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, photochemistry and different disciplines of engineering

•It has a multicultural, multilingual and multinational work- force of more than 4000 employee including 200 people outside Indian 49countries of Africa,CIS,Japan,USA

•First Indian company to get IND approval by USFDAIt has four more INDs with USDFA

•One for pulmonary tuberculosis, rest for various type of cancer, e.g., Lung cancer, Prostrate cancer, Bladder cancer and Melanoma

MILESTONEMILESTONE

Best research and development set-ups in the Best research and development set-ups in the countrycountry

Host of BIOTECH product launchedHost of BIOTECH product launched Worlds first manufacture of immuvac-a unique Worlds first manufacture of immuvac-a unique

immunomodulatorimmunomodulator USFDA approvals for fluoxetine and Ethambutol USFDA approvals for fluoxetine and Ethambutol

manufacturing facilitiesmanufacturing facilities Asia’s only manufacture of Asia’s only manufacture of

‘SULFOLANE’(tetramethylene sulfone)‘SULFOLANE’(tetramethylene sulfone) Leadership in domestic marketing and distribution Leadership in domestic marketing and distribution

managementmanagement

INTERNATIONAL INTERNATIONAL BUSINESSBUSINESS A significant presence in the Americas, CIS country, A significant presence in the Americas, CIS country,

Africa, Central and South-east Asia, Oceanic Africa, Central and South-east Asia, Oceanic countries, Japan, Middle East and Europecountries, Japan, Middle East and Europe

It has offices in USA, Japan, Kenya, Nigeria, Russia, It has offices in USA, Japan, Kenya, Nigeria, Russia, Kazakhstan and ukrainKazakhstan and ukrain

International SBU plans to expand operations to International SBU plans to expand operations to more than 100 countries by 2010more than 100 countries by 2010

Focus is on building brands in the following Focus is on building brands in the following therapeutic segments:therapeutic segments:

Anti-infective, Gastrointestinal, Analgesic, Anti-infective, Gastrointestinal, Analgesic, Respiratory, Cardiovascular, Ophthalmology, Respiratory, Cardiovascular, Ophthalmology, Bio-tchnical products Bio-tchnical products

PRODUCT CAPACITYPRODUCT CAPACITY

MAIN PHARMA PRODOTION CAPACITYMAIN PHARMA PRODOTION CAPACITY Tablets: 3900 million/yearTablets: 3900 million/year Capsules: 150 million/yearCapsules: 150 million/year Liquid: 6000 million kilolitres/yearLiquid: 6000 million kilolitres/year Sterile vias: 84 million/yearSterile vias: 84 million/year Ampoules: 84 million/yearAmpoules: 84 million/year Granules: 15.6 tones/yearGranules: 15.6 tones/year

BETA LACTUM /CEPHALOSPORINBETA LACTUM /CEPHALOSPORIN

Dry sterile vials: 48 million/yearDry sterile vials: 48 million/year Dry syrup bottles: 27 million/yearDry syrup bottles: 27 million/year Capsules: 630 million/yearCapsules: 630 million/year Tablets: 510million/yearTablets: 510million/year

CHAMPION BRANDCHAMPION BRAND

ENVASENVAS ACILOCACILOC LMX, SYMBIOTIK,CLAXLMX, SYMBIOTIK,CLAX RABELOCRABELOC ACILOC RD, ZASOACILOC RD, ZASO MIXULIN,MONTELAST,NODONMIXULIN,MONTELAST,NODON First company in INDIA to introduceFirst company in INDIA to introduce RABEPRAZOLE and FOSINPRIL formulations RABEPRAZOLE and FOSINPRIL formulations

PRODUCTPRODUCT

It caters to over 50 therapeutic areasIt caters to over 50 therapeutic areas Cardiovascular, gastrointestinal, analgesics, Cardiovascular, gastrointestinal, analgesics,

haematinics, anti-invectives and antibiotics, haematinics, anti-invectives and antibiotics, respiratory agents, antidiabetics and immunologicalrespiratory agents, antidiabetics and immunological

Biotechonolgy products and digonontic kits, plants Biotechonolgy products and digonontic kits, plants tissue culturetissue culture

Rabies immunoglobin and diagnostic kits for Rabies immunoglobin and diagnostic kits for detection of HIV and HCVdetection of HIV and HCV

Companies also manufacturer tablet Companies also manufacturer tablet presses,capsule filling machine,pharma machinery presses,capsule filling machine,pharma machinery parts and hospital disposables like glovesparts and hospital disposables like gloves

MARKETING DIVISIONSMARKETING DIVISIONS

Magna-Practitioners, physicians, Magna-Practitioners, physicians, surgeons cardiologists, surgeons cardiologists, gastroenterologistsgastroenterologists

Maxima-Chest physians, Dentists, Maxima-Chest physians, Dentists, surgeons surgeons

Volta-cardiology, diabetology, Volta-cardiology, diabetology, nephrology, critical carenephrology, critical care

Oncocare –cadigran, caditrex,karplat,Oncocare –cadigran, caditrex,karplat,

FINANCIAL STATEMENT OF FINANCIAL STATEMENT OF CADILA HEALTHCARE OF CADILA HEALTHCARE OF 2006-072006-07

20062006 20072007 INCREASEINCREASE

TOTAL TOTAL INCOMEINCOME

Rs Rs 3754millio3754millionn

Rs4629millRs4629millionion

23.31%23.31%

NET SALENET SALE RS RS 3572millio3572millionn

Rs Rs 4429millio4429millionn

23.99%23.99%

NET NET PROFITPROFIT

Rs Rs 429million429million

Rs Rs 664million664million

34.96%34.96%

THANK YOUTHANK YOU